Biotech Values

[jq1234]

>> PD-L1-positive subgroup was defined as patients with PD-L1 expression ≥1%.


Worth noting, Roche's definition of PD-L1 here is based on immune cell (IC): "PD-L1 expression was assessed on tumour-infiltrating immune cells (IC) with an investigational immunohistochemistry (IHC) test based on the SP142 antibody being developed by Roche Tissue Diagnostics", while MRK/BMY/AZN diagnostics on PD-L1 expressions are based on tumor cell (TC). They are different. Roche had provided both sometimes in the past, stated PD-L1 expression on tumor infiltrating immune cells (IC) predicts responses to atezolizumab better than PD-L1 expression on tumor cells (TC).